tradingkey.logo

OmniAb Inc

OABIW

0.290USD

+0.010+3.57%
Market hours ETQuotes delayed by 15 min
0.00Market Cap
--P/E TTM

OmniAb Inc

0.290

+0.010+3.57%
More Details of OmniAb Inc Company
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Company Info
Ticker SymbolOABIW
Company nameOmniAb Inc
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address5980 Horton Street
CityEMERYVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94608
Phone15102507800
Websitehttps://www.omniab.com/
Ticker SymbolOABIW
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
27
14.22M
0.00%
-4.45M
2025Q1
30
14.22M
0.00%
-4.87M
2024Q4
31
14.27M
0.00%
-4.01M
2024Q3
40
15.02M
0.00%
-4.74M
2024Q2
44
16.42M
0.00%
-4.17M
2024Q1
44
16.68M
0.00%
-3.92M
2023Q4
44
16.86M
0.00%
+8.02M
2023Q3
42
5.61M
0.00%
-2.94M
2023Q2
41
5.80M
0.00%
-2.20M
2023Q1
39
5.66M
0.00%
-2.25M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Walleye Trading, LLC
--
0%
-22.51K
-100.00%
Dec 31, 2024
Susquehanna International Group, LLP
--
0%
-16.35K
-100.00%
Mar 31, 2024
Avista Capital Holdings, LP
11.35M
0%
--
--
Sep 30, 2024
LMR Partners LLP
897.39K
0%
--
--
Mar 31, 2025
Aristeia Capital, L.L.C.
692.92K
0%
--
--
Mar 31, 2025
Hudson Bay Capital Management LP
465.23K
0%
-2.75K
-0.59%
Mar 31, 2025
Sculptor Capital Management, Inc
339.40K
0%
--
--
Mar 31, 2025
Calamos Advisors LLC
200.00K
0%
--
--
Mar 31, 2025
MMCAP Asset Management
158.33K
0%
--
--
Mar 31, 2025
Wolverine Asset Management, LLC
1.55K
0%
-70.33K
-97.85%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI